Update on the FRP Investigation
SkinBioTherapeutics plc has announced that FRP Advisory is nearing the completion of its forensic investigation, with a report expected for the Board in the coming days. Following a review of these findings and consultation with external advisors, the company will finalize its HY26 results and restate its unaudited FY25 results as soon as practicable.
Select text to share a quote on X · sign in to keep highlights & notes in your SBTX notes
29 April 2026 - the Board of SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, announces that FRP Advisory is in the final stages of its forensic investigation and is expected to provide its report to the Board in the coming days.
Once the Board has had the opportunity to review the findings, taken appropriate advice from its external advisers, and considered the regulatory and governance implications of the investigation, it will finalise the HY26 results with the restated (unaudited) FY25 results as soon as practicable.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.